Minimal residual disease (MRD) as a marker of antileukemic drug efficacy is being used to assess risk status and, in some cases, to adjust the intensity of therapy.
MRD作为抗白血病药物疗效标志,被用
评估患者危险,在某些病
中也用
疗强度。
Minimal residual disease (MRD) as a marker of antileukemic drug efficacy is being used to assess risk status and, in some cases, to adjust the intensity of therapy.
MRD作为抗白血病药物疗效标志,被用评估患者危险,在某些病中也用疗强度。
声明：以上
、词性分类均由互联网资源自动生成，部分未经过人工审核，其表达内容亦不代表本软件的观点；若发现问题，欢迎向我们指正。
